11 HaMenofim Street
972 9 799 6183
Full-time employees: 11
|Mr. Alon Ben-Noon||Co-Founder, CEO & Director||N/A||N/A||1979|
|Mr. Or Eisenberg||Chief Financial Officer||N/A||N/A||1981|
|Ms. Hagit Binder||VP of Operations||N/A||N/A||1978|
|Ms. Yael Barak||Head of QA & Compliance||N/A||N/A||1970|
|Ms. Nedira Salzman-Frenkel||Global Head of Bus. Devel.||N/A||N/A||1988|
|Dr. Shiran Zimri Ph.D.||Head of Scientific Program||N/A||N/A||1985|
|Dr. Ferenc Tracik M.D.||Chief Medical Officer||N/A||N/A||1965|
|Dr. Niva Russek-Blum Ph.D.||Global Head of Discovery & IP Generator||N/A||N/A||1975|
|Dr. Sharon Cohen Vered Ph.D.||Global Head of CMC||N/A||N/A||1966|
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.